MabCampath (alemtuzumab)
- Region
- 🇪🇺 EU
- Active substance
- alemtuzumab
- Company
- Genzyme Europe B.V.
- Status
- Withdrawn
- Therapeutic area
- Leukemia, Lymphocytic, Chronic, B-Cell
- EU approval
- Fri 06 Jul 2001
- Application
- EMEA/H/C/000353
- ATC
- L01XC04
- Official record
- www.ema.europa.eu
Indication
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Lemtrada Authorised · Sanofi Belgium
Follow MabCampath
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.